Zealand Pharma slides on safety concerns around survodutide
Zealand Pharma’s shares fell about 25-26% after late-stage survodutide data showed notable GI adverse events, with a 19% discontinuation rate and more than 40% of patients reporting vomiting, raising questions about safety/tolerability despite up to 16.6% average weight loss versus placebo. Analysts warned the safety profile could limit commercial potential amid strong competition from Novo Nordisk and Eli Lilly, contributing to a steep year-to-date decline as Zealand works with Boehringer Ingelheim and Roche.